Furthermore, prior studies have demonstrated that the upregulation of inflammatory and interferon-gamma (IFNγ) signaling-related gene signatures in inoperable EAC patients serve as on-treatment markers of ICI efficacy, while the elevated expression of E2F targets and genes related to extracellular matrix has been associated with tumor growth and resistance to ICI treatment [24]. This evidence concerns the gene IFNG and neoplasm.